Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
0.907
+0.007 (0.72%)
At close: Nov 22, 2024, 4:00 PM
0.910
+0.003 (0.29%)
After-hours: Nov 22, 2024, 7:45 PM EST
Ocugen Revenue
Ocugen had revenue of $1.14M in the quarter ending September 30, 2024, a decrease of -69.29%. This brings the company's revenue in the last twelve months to $4.70M, down -33.94% year-over-year. In the year 2023, Ocugen had annual revenue of $6.04M with 142.60% growth.
Revenue (ttm)
$4.70M
Revenue Growth
-33.94%
P/S Ratio
50.66
Revenue / Employee
$72,308
Employees
65
Market Cap
264.34M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Zynex | 193.67M |
Anika Therapeutics | 164.17M |
Poseida Therapeutics | 150.86M |
Lifecore Biomedical | 128.44M |
NeuroPace | 76.45M |
Precigen | 3.96M |
Artiva Biotherapeutics | 2.60M |
Atai Life Sciences | 331.00K |
OCGN News
- 3 days ago - Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease - GlobeNewsWire
- 4 days ago - Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire
- 15 days ago - Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Ocugen Provides Business Update with Third Quarter 2024 Financial Results - GlobeNewsWire
- 16 days ago - Ocugen Secures $30 Million in Debt Funding - GlobeNewsWire
- 26 days ago - Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 - GlobeNewsWire
- 4 weeks ago - Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease - GlobeNewsWire
- 5 weeks ago - Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results - GlobeNewsWire